Coherex Medical, Inc. Announces CE Mark for the WaveCrest LAA Occlusion System

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY--(BUSINESS WIRE)--Coherex Medical, Inc. announced it has received CE Mark approval for its Coherex WaveCrest™ LAA Occlusion System.

Atrial fibrillation (AF) is the most common cardiac arrhythmia in today’s aging population, affecting nearly 6 million individuals in the US alone. AF causes the upper chambers of the heart to beat irregularly, slowing the flow of blood through these chambers and increasing the risk for stroke as this slower blood flow can cause clots to form.

Help employers find you! Check out all the jobs and post your resume.

Back to news